Drugs / VXM01
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02718443 | May 2016 → Aug 2017 | glioblastoma | Vaximm GmbH | Completed | No outcome recorded |
| Phase 1 | NCT02718430 | Feb 2016 → Mar 2018 | colorectal cancer | Vaximm GmbH | Completed | No outcome recorded |
| Phase 1 | NCT01486329 | Dec 2011 → Oct 2014 | pancreas disorder | Vaximm GmbH | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03750071 | Nov 2018 → Dec 2021 | glioblastoma | Vaximm GmbH | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VXM01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01486329 ↗ |
| Action | Inhibit | “The immune reaction elicited by VXM01 is expected to disrupt the tumor neovasculature and, consequently, inhibit tumor growth.” PMID 22906006 ↗ Aug 2012 |
| Modality | Vaccine | “The investigational oral DNA vaccine VXM01 targets the vascular endothelial growth factor receptor 2 (VEGFR-2) and uses Salmonella typhi Ty21a as a vector.” PMID 22906006 ↗ Aug 2012 |
| Route | Oral | “The investigational oral DNA vaccine VXM01 targets the vascular endothelial growth factor receptor 2 (VEGFR-2)” PMID 22906006 ↗ Aug 2012 |